T Cell Responses to AAV Vector Capsid Limit the Duration of Transgene Expression in Humans after Liver-Directed Gene Therapy.
Federico Mingozzi(Spark Therapeutics (United States)), Katherine A. High(Spark Therapeutics (United States)), Catherine S. Manno(Children's Hospital of Philadelphia), Daniel J. Hui(Children's Hospital of Philadelphia), Margareth V. Ragni(University of Pittsburgh), Marcela V. Maus(Center for Cancer Research), Denise E. Sabatino(Children's Hospital of Philadelphia)
Cited by 3
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Gene therapy comes of age
|Science|2018|1.4k